New combo shrinks liver tumors before surgery in early trial
NCT ID NCT04857684
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This early-phase study tests whether giving focused radiation and two immunotherapy drugs before surgery can safely help treat liver cancer that can be removed. About 20 adults with resectable hepatocellular carcinoma will receive stereotactic body radiation therapy (SBRT) followed by atezolizumab and bevacizumab, then surgery. The main goal is to check safety and side effects, with secondary aims looking at tumor shrinkage and surgical success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.